Loading stock data…
MPLT
$30.70-1.17 (-3.67%)
Market ClosedLast close May 1
MapLight Therapeutics, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$30.70
Potential Upside
5%
Whystock Fair Value$32.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarini...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.16%
Volume
Today's trading volume
217,168
Recent News
We're Hopeful That MapLight Therapeutics (NASDAQ:MPLT) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data
This clinical-stage biotech focused on CNS disorders reported a notable insider sale, as disclosed in its latest SEC filing.
TD Cowen Initiates on MapLight (MPLT); Says It’s Undervalued on Schizophrenia Alone
MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of the must-buy small cap stocks to buy. On April 7, TD Cowen analyst Joseph Thome initiated coverage on MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Buy rating. The analyst cited the company’s pipeline of treatments targeting the central nervous system, or CNS, and neuropsychiatric conditions. Thome’s bullish thesis is […]
MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying
MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 8, 2026, Needham initiated coverage of MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Buy rating and a $37 price target. Needham said the muscarinic class could be “disruptive” across multiple indications, including schizophrenia and Alzheimer’s disease psychosis, and noted ML-007C-MA […]
Sector Update: Health Care Stocks Increase Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index and the Health Care S